Abstract: TH-PO1240
Finerenone in Patients with FSGS: A FIND-CKD Analysis
Session Information
- Late-Breaking Research Posters
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Heerspink, Hiddo Jan L., George Institute for Global Health, University of New South Wales, Sydney, Australia
- Agarwal, Rajiv, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, Indiana, United States
- Cherney, David, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
- Lam, Carolyn S.P., National Heart Centre Singapore, Singapore, Singapore
- Neuen, Brendon Lange, George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
- Tuttle, Katherine R., University of Washington School of Medicine, Spokane, Washington, United States
- Wanner, Christoph, Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany
- Sarafidis, Pantelis, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Barratt, Jonathan, University of Leicester and Leicester General Hospital, Leicester, United Kingdom
- Floege, Jürgen, RWTH Aachen University Hospital, Aachen, Germany
- Smeijer, Johannes David, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
- Jongs, Niels, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
- Berger, Mario, Bayer AG, Wuppertal, Germany
- Brinker, Meike Daniela, Bayer AG, Wuppertal, Germany
- Dayoub, Rania, Bayer AG, Berlin, Germany
- Finkelsztein, Marina Yael, EuroServices Bayer, S.L., Barcelona, Spain
- Schloemer, Patrick, Bayer AG, Berlin, Germany
- Perkovic, Vlado, University of New South Wales, Sydney, New South Wales, Australia
Background
The FIND-CKD trial showed that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces eGFR decline and urinary albumin-to-creatinine ratio (UACR) in patients with non-diabetic CKD. This prespecified subanalysis examines the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS).
Methods
The FIND-CKD trial randomized 1584 participants with non-diabetic CKD (eGFR 25 to <90 mL/min/1.73 m2 and UACR 200 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg orally) or placebo. Outcomes reported here included total eGFR slope (baseline to month 32), a kidney composite (sustained ≥40% eGFR decline from baseline or kidney failure), changes in urinary protein-to-creatinine ratio (UPCR) and UACR over time, and adverse events.
Results
Among 215 participants with FSGS, the mean baseline eGFR was 45 mL/min/1.73 m2 and the median UACR was 954 mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS, and 78% (n=167) had a recorded kidney biopsy. Total eGFR slope (mL/min/1.73 m2/year) over 32 months was significantly reduced with finerenone vs placebo (difference: 1.3 [95% CI 0.5–2.2; p=0.02]; Figure). This effect was consistent among participants with primary or secondary FSGS (pinteraction=0.84). Finerenone yielded a hazard ratio of 0.60 (95% CI 0.35–1.03) vs placebo for the kidney composite outcome. From baseline to month 6, finerenone lowered UACR by 36% (95% CI 25%–45%) and UPCR by 38% (95% CI 26%–48%) vs placebo. Finerenone increased the likelihood of achieving UPCR <700 mg/g at month 6 vs placebo (odds ratio 5.1 [95% CI 2.3–12.4]). Hyperkalemia was the most common adverse event.
Conclusion
Finerenone preserved kidney function, lowered UPCR, and was well tolerated in participants with FSGS.
Funding
- Commercial Support – Bayer AG